



September 12, 2005

EUROPEAN PATENT OFFICE
P.B. 5818
Patentlaan 2
GERMANY
Fax: 31-70-340-3016
Authorized Officer: Zervas, B.

Re: International Application No. PCT/IB2005/000872
Warner-Lambert Company LLC
Docket No. PC32134APCT

**RESPONSE TO WRITTEN OPINION OF THE INTERNATIONAL
PRELIMINARY EXAMING AUTHORITY**

Dear Sirs,


This communication is being submitted in response to the Written Opinion of the International Searching Authority dated June 29, 2005. A Demand was filed for the above referenced application on June 15th, 2005. Thus, this communication is directed to the International Preliminary Examining Authority ("IPEA"). The IPEA has rejected claims 1, 3, 5, 6 and 8-9 as lacking novelty. The IPEA has acknowledged that claims 2, 4, 7, and 10-15 are novel and possess an inventive step.

In order to advance the prosecution of this application, claim 1 has been amended. Claim 1, as amended, specifies that at least one of R¹ or R² must be represented by C₁-C₆ alkyl, which may optionally be substituted. Support for this amendment may be found on page 13 of the specification, lines 5-7, where it


states that typically one of R¹ or R² will be C₁-C₆ alkyl and the other may be hydrogen or C₁-C₆ alkyl. The term "prodrug" has also been deleted from claim 1.

It is respectfully submitted that this amendment removes the novelty objections raised by the IPEA. The IPEA has acknowledged that claim 2, directed to a subgenus of lower alkyl's is novel and possess an inventive step. A positive International Preliminary Examiner Report is respectfully requested.

Replacement pages 115 to 118 containing the amended claims accompany this letter.



Date
Warner-Lambert Company LLC
Patent Department
2800 Plymouth Road
Ann Arbor, MI 48105
(734) 622-1705

Respectfully submitted,


J. Michael Dixon
Attorney for Applicant(s)
Reg. No. 32,410

CLAIMS

1. A compound of the formula:



in which;

- a) X^1 is represented by cyano, halogen or haloalkyl,
- b) one of R^1 or R^2 is represented by $\text{C}_1\text{-C}_6$ alkyl which may be optionally substituted, and the other of R^1 or R^2 is represented by hydrogen or $\text{C}_1\text{-C}_6$ alkyl which may be optionally substituted,
- c) Alk^1 is represented by a $\text{C}_1\text{-C}_2$ linear alkylene group, in which up to two hydrogen atoms are optionally replaced by a substituent selected from the group consisting of $\text{C}_1\text{-C}_6$ alkyl optionally substituted, halogen, hydroxy, thiol, and cyano,
- d) n is represented by the integer 0 or 1,
- e) Y is represented by NX^2X^3 or O-X^3 ,
- f) X^2 is represented by hydrogen or $(\text{C}_1\text{-C}_6)$ alkyl optionally substituted,
- g) X^3 is represented by
- hydrogen,
 - $(\text{C}_1\text{-C}_{12})$ alkyl, optionally substituted,
 - $(\text{C}_2\text{-C}_{12})$ alkenyl, optionally substituted,
 - $(\text{C}_2\text{-C}_{12})$ alkynyl, optionally substituted,
 - $(\text{C}_3\text{-C}_{10})$ cycloalkyl, optionally substituted,
 - $(\text{C}_3\text{-C}_{10})$ cycloalkyl $(\text{C}_1\text{-C}_6)$ alkyl, in which the alkyl and cycloalkyl moieties may each be optionally substituted,
 - $(\text{C}_6\text{-C}_{10})$ aryl, optionally substituted,

Pat
B
1.3

- viii. $(C_6-C_{10})\text{aryl}(C_1-C_6)\text{alkyl}$, in which the alkyl and aryl moieties may each be optionally substituted,
- ix. $-(CH_2)-(Alk^2)_q-C(O)R^3$, in which Alk^2 is represented by a (C_1-C_8) linear alkylene group, in which up to eight hydrogen atoms may optionally be replaced by a substituent, selected from the group consisting of (C_1-C_6) alkyl optionally substituted, (C_1-C_6) alkoxy, halogen, hydroxy, thiol, cyano, and NR^8R^9 in which R^8 and R^9 are each independently represented by hydrogen or (C_1-C_6) alkyl, q is the integer 0 or 1, R^3 is represented by hydrogen, $(C_1-C_{12})\text{alkyl}$, $(C_6-C_{10})\text{aryl}$, or $(C_6-C_{10})\text{aryl}(C_1-C_6)\text{alkyl}$, in which the alkyl and aryl moieties may each be optionally substituted,
- x. $-(CH_2)-(Alk^2)_q-C(O)-O-R^4$, in which Alk^2 and q , are as defined above, and R^4 is represented by hydrogen, $(C_1-C_{12})\text{alkyl}$, $(C_6-C_{10})\text{aryl}$, or $(C_6-C_{10})\text{aryl}(C_1-C_6)\text{alkyl}$, in which the alkyl and aryl moieties may be optionally substituted,
- xi. $-(CH_2)-(Alk^2)_q-C(O)-NR^5R^6$ in which Alk^2 and q are as described above, and R^5 and R^6 are each independently represented by hydrogen, $(C_1-C_{12})\text{alkyl}$, $(C_6-C_{10})\text{aryl}$, or $(C_6-C_{10})\text{aryl}(C_1-C_6)\text{alkyl}$, in which the alkyl and aryl moieties may be optionally substituted,
- xii. $-(CH_2)-(Alk^2)_q-Y-R^7$, in which Alk^2 and q are as defined above, Y is O or S, and R^7 is selected from the group consisting of hydrogen, $(C_1-C_{12})\text{alkyl}$, $(C_6-C_{10})\text{aryl}$, or $(C_6-C_{10})\text{aryl}(C_1-C_6)\text{alkyl}$, in which the alkyl and aryl moieties may be optionally substituted,
- xiii. heteroaryl, optionally substituted,
- xiv. heteroaryl $(C_1-C_6)\text{alkyl}$, in which the heteroaryl and alkyl moieties may each be optionally substituted,

- xv. heterocyclic, optionally substituted,
- xvi. heterocyclic(C₁-C₆)alkyl, in which the alkyl and heterocyclic moieties may each be substituted, or,

h) for those compounds in which Y is N, X² and X³, along with the adjacent nitrogen atom, may form a heterocyclic ring, which may optionally be substituted;
or a salt or solvate thereof.

2. A compound according to claim 1 in which one of R¹ or R² is hydrogen and the other of R¹ or R² is selected from the group consisting of isobutyl, propyl, n-butyl, isopropyl, and ethyl.
3. A compound according to claim 1 or 2 in which n is 0.
4. A compound according to claim 1, 2, or 3 in which X¹ is trifluoromethyl and is located at the 3-position of the phenyl ring.
5. A compound according to claim 1, 2, 3, or 4 in which Y is NX²X³.
6. A compound according to claim 5 in which X² is hydrogen.
7. A compound according to claim 6 in which X³ is represented by a substituent selected from the group consisting of (C₁-C₁₂)alkyl, (C₃-C₁₀)cycloalkyl(C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₆)alkyl, heteroaryl(C₁-C₆)alkyl, and heterocyclic(C₁-C₆)alkyl.
8. A compound according to claim 1, 2, 3, or 4 in which Y is OX³.
9. A compound according to anyone of claims 1-8 in which X¹ is represented by halogen or haloalkyl.
10. Use of a compound according to anyone of claims 1-9 as a medicine.

11. Use of a compound according to anyone of claims 1-9 in the manufacture of a medicament for inhibiting activation of the androgen receptor
12. Use of a compound according to anyone of claims 1-9 in the manufacture of a medicament for the alleviating a condition selected from the group consisting of hormone dependent cancers, benign hyperplasia of the prostate, acne, hirsutism, excess sebum, alopecia, premenstrual syndrome, lung cancer, precocious puberty, osteoporosis, hypogonadism, age-related decrease in muscle mass, and anemia.
13. A pharmaceutical composition comprising a compound according to anyone of claims 1-9 in admixture with 1, or more, pharmaceutically acceptable excipients.
14. A topical pharmaceutical formulation comprising a compound according to anyone of claims 1-9 in admixture with 1, or more, pharmaceutically acceptable excipients suitable for dermal application.
15. An article of manufacture comprising a compound according to anyone of claims 1-9 packaged for retail distribution, which advises a consumer how to utilize the compound to alleviate a condition selected from the group consisting of acne, alopecia, and oily skin.